EGEleonora Ghisoni

Eleonora Ghisoni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eleonora Ghisoni has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandre Harari

    Department of Oncology UNIL CHUV, University of Lausanne, Lausanne, Switzerland

    1 shared publication
  • Alizée J. Grimm

    Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland

    1 shared publication
  • Angela Orcurto

    Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland

    1 shared publication
  • Anne I. Kraemer

    Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland

    1 shared publication
  • Blanca Navarro

    Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland

    1 shared publication
  • Charitini Andriakopoulou

    Scientific Research Consulting Hellas, Athens, Greece

    1 shared publication

Latest Publications

  • Top Cited Papers

    Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma

    by David Barras, Eleonora Ghisoni, Johanna Chiffelle, Angela Orcurto, Julien Dagher, Noémie Fahr, Fabrizio Benedetti, Isaac Crespo, Alizée J. Grimm, Matteo Morotti, et al.

    Adoptive cell therapy (ACT) using ex vivo–expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples from 13 patients with metastatic melanoma treated with TIL-ACT in a phase 1 clinical study, we interrogated cellular states within the tumor microenvironment (TME) and their interactions. We performed bulk and single-cell RNA sequencing, whole-exome sequencing, and spatial proteomic analyses in pre- and post-ACT tumor tissues, finding that ACT responders exhibited higher basal tumor cell–intrinsic immunogenicity and mutational burden. Compared with nonresponders, CD8 + TILs exhibited increased cytotoxicity, exhaustion, and costimulation, whereas myeloid cells had increased type I interferon signaling in responders. Cell-cell interaction prediction analyses corroborated by spatial neighborhood analyses revealed that responders had rich baseline intratumoral and stromal tumor–reactive T cell networks with activated myeloid populations. Successful TIL-ACT therapy further reprogrammed the myeloid compartment and increased TIL-myeloid networks. Our systematic target discovery study identifies potential T-myeloid cell network–based biomarkers that could improve patient selection and guide the design of ACT clinical trials.